Interim Analysis Finds DOXIL(R)/VELCADE(R) Combination Significantly Prolongs Time To Progression In Previously Treated Multiple Myeloma Patients

Tue, 12 Dec 2006 02:00 PM EST

... Researchers investigating the combination of DOXIL(R) (doxorubicin HCl liposome injection) and VELCADE(R) (bortezomib), the market leader in relapsed or refractory multiple myeloma (MM), report that the combination of medications provides a nearly three-month improvement in time to disease [click link for full article] ...